Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Botanical or Opioid or [[:Category:Androgen_modulators|Androgen modulator]]

Use the filters below to narrow your results.

generic:
Codeine (2)
brand:
None (32) · (multiple, generic dominant) (1) · Alfenta (1) · Avodart; combined with tamsulosin as Jalyn (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Dolophine (1) · Duragesic (1) · Heroin (1) · Krokodil (1) · Nubain (1) · Nucynta (1) · O-DSMT (1) · Opana (1) · Proscar (5 mg, BPH), Propecia (1 mg, alopecia) (1) · Stablon (1) · Stadol (1) · Suboxone (1) · Sufenta (1) · Talwin (1) · Ultiva (1) · Vicodin (1)
classes: (Click arrow to add another value)
mechanism:
Potent mu-opioid receptor agonist (6) · Mu-opioid receptor agonist (4) · None (2) · Contains LSA (2) · Contains mescaline (2)
uses:
None (51) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-0000052E-QINU`"', '"`UNIQ--vote-0000052F-QINU`"', '"`UNIQ--vote-00000530-QINU`"' (1) · '"`UNIQ--vote-00000D57-QINU`"', '"`UNIQ--vote-00000D58-QINU`"' (1)
starting dose:
None (51) · 0.5 mg PO once daily (1) · 5 mg PO daily for BPH; 1 mg PO daily for androgenetic alopecia (1) · Adult: 15–60 mg every 4 hours as needed. (1)
preparations:
None (51) · 0.5 mg capsules (1) · 1 mg, 5 mg tablets (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
None (51) · 0.5 mg/d (1) · 360 mg/day (1) · 5 mg/d (1)
routes:
None (51) · Oral (2) · PO (only formulation marketed in the US). (1)
onset:
None (51) · 30–60 min (PO) (1) · BPH symptom improvement at 3-6 months; prostate volume reduction over 6-12 months; hair regrowth at 6-12 months (1) · Prostate volume reduction over 6-12 months (1)
duration:
None (51) · 24 hours (1) · 24 hours; tissue effects persist weeks (1) · 4–6 hours (1)
halflife:
None (51) · 2.5–3 hours (1) · ~5 weeks (much longer than finasteride's ~6 hours)'"`UNIQ--ref-00000D59-QINU`"' (1) · ~5-6 hours in young men, ~8 hours in elderly'"`UNIQ--ref-00000531-QINU`"' (1)
bioavailability:
None (51) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~60% (oral)'"`UNIQ--ref-00000D5A-QINU`"' (1) · ~63% (oral)'"`UNIQ--ref-00000532-QINU`"' (1)
pregnancy:
None (51) · '''Pregnant individuals should not handle crushed/broken tablets''' (skin absorption risk); can cause hypospadias in male fetus. Not used in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · '''Pregnant individuals should not handle dutasteride capsules''' (skin absorption risk through intact capsule); can cause hypospadias in male fetus.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1)
legal:
None (51) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (2)

Showing below up to 57 results in range #1 to #57.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"